Clinical Course and Outcomes of Severe Covid-19: A National Scale Study.
ARDS
ICU
comorbidities
covid-19
mortality
prognosis
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
18 Jul 2020
18 Jul 2020
Historique:
received:
11
06
2020
revised:
05
07
2020
accepted:
08
07
2020
entrez:
26
7
2020
pubmed:
28
7
2020
medline:
28
7
2020
Statut:
epublish
Résumé
Knowledge of the outcomes of critically ill patients is crucial for health and government officials who are planning how to address local outbreaks. The factors associated with outcomes of critically ill patients with coronavirus disease 2019 (Covid-19) who required treatment in an intensive care unit (ICU) are yet to be determined. This was a retrospective registry-based case series of patients with laboratory-confirmed SARS-CoV-2 who were referred for ICU admission and treated in the ICUs of the 13 participating centers in Israel between 5 March and 27 April 2020. Demographic and clinical data including clinical management were collected and subjected to a multivariable analysis; primary outcome was mortality. This study included 156 patients (median age = 72 years (range = 22-97 years)); 69% (108 of 156) were male. Eighty-nine percent (139 of 156) of patients had at least one comorbidity. One hundred three patients (66%) required invasive mechanical ventilation. As of 8 May 2020, the median length of stay in the ICU was 10 days (range = 0-37 days). The overall mortality rate was 56%; a multivariable regression model revealed that increasing age (OR = 1.08 for each year of age, 95%CI = 1.03-1.13), the presence of sepsis (OR = 1.08 for each year of age, 95%CI = 1.03-1.13), and a shorter ICU stay(OR = 0.90 for each day, 95% CI = 0.84-0.96) were independent prognostic factors. In our case series, we found lower mortality rates than those in exhausted health systems. The results of our multivariable model suggest that further evaluation is needed of antiviral and antibacterial agents in the treatment of sepsis and secondary infection.
Identifiants
pubmed: 32708357
pii: jcm9072282
doi: 10.3390/jcm9072282
pmc: PMC7408944
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
J Clin Virol. 2004 Dec;31(4):304-9
pubmed: 15494274
Chest. 2014 Oct;146(4):881-883
pubmed: 25144140
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
JAMA. 2020 Apr 6;:
pubmed: 32250385
Chest. 2014 Oct;146(4 Suppl):8S-34S
pubmed: 25144202
JAMA Intern Med. 2020 Mar 13;:
pubmed: 32167524
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
JAMA. 2020 Mar 19;:
pubmed: 32191259
N Engl J Med. 2020 May 21;382(21):2012-2022
pubmed: 32227758
Am J Respir Crit Care Med. 2018 Mar 15;197(6):757-767
pubmed: 29161116
N Engl J Med. 2020 Apr 23;382(17):1653-1659
pubmed: 32227760
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Lancet. 2003 May 24;361(9371):1767-72
pubmed: 12781535
JAMA. 2020 Feb 7;:
pubmed: 32031570
JAMA. 2020 Apr 22;:
pubmed: 32320003
JAMA. 2013 Jan 16;309(3):275-82
pubmed: 23321766
Crit Care Med. 2020 Feb;48(2):e98-e106
pubmed: 31939808